A proline-rich polypeptide complex (PRP) isolated from ovine colostrum.: Modulation of H2O2 and cytokine induction in human leukocytes

被引：17

作者：

Zablocka, Agnieszka ^{[1
]}

Janusz, Maria ^{[1
]}

Macala, Jozefa ^{[1
]}

Lisowski, Jozef ^{[1
]}

机构：

[1] Polish Acad Sci, Inst Immunol & Expt Therapy, Dept Immunochem, PL-53114 Wroclaw, Poland

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2007年 / 7卷 / 07期

关键词：

proline-rich polypeptide complex (PRP); human peripheral blood mononuclear cells (PBMCs); H2O2; cytokines;

D O I：

10.1016/j.intimp.2007.02.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A proline-rich polypeptide complex (PRP) has immunoregulatory properties and also shows beneficial effects in Alzheimer's disease (AD). It is known that the unregulated activation of microglial cells in AD may result in chronic inflammatory response. There is a link between the activation of immune cells on the periphery and in the central nervous system (CNS). Therefore, we studied the effect of the PRP on human peripheral blood mononuclear cells (PBMCs) stimulated by LPS with PHA (LP) or PMA as proinflammatory activators. PRP and its nonapeptide fragment (NP) inhibited by 40-60% production of H2O2 induced by PMA. The peptides also inhibited activity of superoxide dismutase. Both peptide preparations showed differential effects on the secretion of cytokines. NP induced TNF-alpha only while PRP induced IL-6, IL-10 and TNF-alpha. On the other hand, the release of TNF-alpha and IL- 10 induced by LP in PBMCs was inhibited by PRP while NP inhibited the release of IFN-gamma and IL-10. The results obtained showed that PRP may affect not only adaptive immunity but also innate immunity and thus may regulate secretions of mediators of inflammation. The regulatory effect of the PRP on the innate immunity may shed some light on understanding the beneficial effects of this polypeptide complex in AD patients. (c) 2007 Elsevier B.V. All rights reserved.

引用

页码：981 / 988

页数：8

共 49 条

[21] Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway [J].

Lehnardt, S ;

Massillon, L ;

Follett, P ;

Jensen, FE ;

Ratan, R ;

Rosenberg, PA ;

Volpe, JJ ;

Vartanian, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8514-8519

[22]

Leszek J., 2002, MED SCI MONITOR, V8, pPI93

[23]

Leszek Jerzy, 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P377

[24] Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain [J].

Licastro, F ;

Grimaldi, LME ;

Bonafè, M ;

Martina, C ;

Olivieri, F ;

Cavallone, L ;

Giovanietti, S ;

Masliah, E ;

Franceschi, C .

NEUROBIOLOGY OF AGING, 2003, 24 (07) :921-926

[25] Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals [J].

Lombardi, VRM ;

García, M ;

Rey, L ;

Cacabelos, R .

JOURNAL OF NEUROIMMUNOLOGY, 1999, 97 (1-2) :163-171

[26] Role of superoxide dismutases in oxidative damage and neurodegenerative disorders [J].

Maier, CM ;

Chan, PH .

NEUROSCIENTIST, 2002, 8 (04) :323-334

[27] Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo [J].

Milatovic, Dejan ;

Zaja-Milatovic, Snjezana ;

Montine, Kathleen S. ;

Shie, Feng-Shiun ;

Montine, Thomas J. .

JOURNAL OF NEUROINFLAMMATION, 2004, 1 (1)

[28] Immunotherapeutic approaches to Alzheimer's disease [J].

Monsonego, A ;

Weiner, HL .

SCIENCE, 2003, 302 (5646) :834-838

[29]

MUBERMAN M, 1994, J NEUROIMMUNOL, V52, P147

[30]

Panaro M. A., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P210, DOI 10.2174/1568008033340216

← 1 2 3 4 5 →